Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Number of holders
-
47
-
Total 13F principal, excl. options
-
744,169,000
-
Principal change
-
+18,393,869
-
Total reported value, excl. options
-
$621,973,473
-
Value change
-
+$15,191,167
-
Number of buys
-
22
-
Number of sells
-
-25
-
Price
-
$0.8343
Significant Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q3 2019
56 filings reported holding 53220KAF5 - LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q3 2019.
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 has 47 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $744,169,000 of principal
.
Largest 10 bondholders include Allianz Asset Management GmbH ($98,640,000 of principal), CANYON CAPITAL ADVISORS LLC ($69,000,000 of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($63,124,000 of principal), CAMDEN ASSET MANAGEMENT L P /CA ($58,450,000 of principal), STEELHEAD PARTNERS LLC ($55,050,000 of principal), CITADEL ADVISORS LLC ($43,711,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($34,133,000 of principal), Polar Capital LLP ($32,000,000 of principal), CNH PARTNERS LLC ($23,325,000 of principal), and Davidson Kempner Capital Management LP ($22,500,000 of principal).
This table shows the top 47 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.